Novartis Cuts 6 Early Cancer Candidates, Adds 2 to Refine Oncology Strategy

Despite the Phase 1 cull, CEO Vas Narasimhan on Wednesday maintained that Novartis continues to invest in its early-stage pipeline, looking for deals in the “sub-$2-billion range.”